Russell Investments Group Ltd. Buys 1,862 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Russell Investments Group Ltd. lifted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 950.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,058 shares of the company’s stock after buying an additional 1,862 shares during the period. Russell Investments Group Ltd.’s holdings in Amphastar Pharmaceuticals were worth $60,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. TD Asset Management Inc raised its position in Amphastar Pharmaceuticals by 20.2% during the first quarter. TD Asset Management Inc now owns 2,212,142 shares of the company’s stock valued at $64,130,000 after purchasing an additional 371,856 shares in the last quarter. Boston Trust Walden Corp raised its stake in Amphastar Pharmaceuticals by 24.2% during the first quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company’s stock worth $35,241,000 after buying an additional 236,704 shares during the last quarter. Northern Trust Corp raised its stake in Amphastar Pharmaceuticals by 5.1% during the fourth quarter. Northern Trust Corp now owns 613,170 shares of the company’s stock worth $22,767,000 after buying an additional 29,808 shares during the last quarter. Royce & Associates LP raised its stake in Amphastar Pharmaceuticals by 2,684.3% during the first quarter. Royce & Associates LP now owns 247,858 shares of the company’s stock worth $7,185,000 after buying an additional 238,956 shares during the last quarter. Finally, Systematic Financial Management LP bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at $9,147,000. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ:AMPH opened at $29.19 on Friday. The stock has a fifty day simple moving average of $25.08 and a two-hundred day simple moving average of $25.75. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of 10.93 and a beta of 0.80. Amphastar Pharmaceuticals, Inc. has a 12-month low of $20.39 and a 12-month high of $53.96. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80.

Analyst Ratings Changes

A number of research firms have weighed in on AMPH. Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Tuesday, August 12th. Wells Fargo & Company dropped their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, May 8th. Finally, Bank of America lifted their target price on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $31.60.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.